We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Antilymphoid Sera in Renal Allotransplantation

Roy G. Shorter, MD; George A. Hallenbeck, MD; Carlos Nava, MD; Hugh O. O'Kane, MB, BSc, FRCS; James H. DeWeerd, MD; William J. Johnson, MD
Arch Surg. 1968;97(2):323-329. doi:10.1001/archsurg.1968.01340020187022.
Text Size: A A A
Published online


BECAUSE of observations by others1-7 on the effects of heterologous antilymphoid sera (ALS) and experiences in the laboratory with the use of antithymus serum as the single immunosuppressive agent in achieving prolongation of survival of allografts of skin (P. Sutthiwan et al, unpublished data) and xenografts of tumor in mice8 we decided to test the immunosuppressive effects of such sera in the allografting of livers and kidneys in dogs, and subsequently to proceed with a trial of the material in the clinical renal transplant program at the Mayo Clinic. The experiments involving hepatic allografting in dogs have been reported elsewhere,9 and the purposes of this presentation are to describe the results obtained in canine renal allografting and to review the findings of a preliminary clinical trial in human beings. In animals, the sera were used as the sole means of immunosuppression; in the clinical situation, however, testing


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.